Studies on the antigenicity and nucleotide sequence of the rabies virus Nishigahara strain, a current seed strain used for dog vaccine production in Japan.
The Nishigahara strain of rabies virus, a current seed strain used for animal vaccine production in Japan, is believed to derived from the original Pasteur strain obtained from Paris in or before 1915. In Japan, the virus was serially passaged through several kinds of animals and cell cultures. Reactions with anti-nucleocapsid protein monoclonal antibodies (MAb-N) indicated the Nishigahara strain had maintained the antigenic profile of the Pasteur virus. Reactions with monoclonal antibodies to the glycoprotein (MAb-G) revealed differences between the Nishigahara strain and the Pasteur strain; however, the Nishigahara strain maintained a closer resemblance to the Pasteur virus than to other Pasteur-related viruses or to rabies strains unrelated to the Pasteur strain. Comparative amino acid sequence analysis of cloned cDNA encoding the G gene confirmed the antigenic differences among these strains and the resemblance of the Nishigahara strain to the original Pasteur strain. Comparative nucleotide sequence analysis of the noncoding pseudogene region (Tordo et al., Proc Natl Acad Sci USA 83, 3914-3918, 1986) revealed different relationships. Unlike the Pasteur strain, which encodes a transcription-terminating signal at the end of the G gene (marking the beginning of the pseudogene), a long G-L intergenic sequence in the Nishigahara strain was connected to the 3' end of the cDNA, and the transcription-terminating signal was present only at the end of, but not before, the pseudogene. These results are not inconsistent with the documented origin of the Nishigahara strain, but the genome structure around the pseudogene region suggests divergence from the Pasteur strain and a closer resemblance to other strains of rabies virus.
Sakamoto
S
S
Research and Development Department, Chemo-Sero-Therapeutic Research Institute (Kaketsuken), Kumamoto, Japan.
Ide
T
T
Nakatake
H
H
Tokiyoshi
S
S
Yamamoto
M
M
Kawai
A
A
Smith
J S
JS
D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal; D000956:Antigens, Viral / Q000235:genetics; D001483:Base Sequence; D018076:DNA, Complementary / Q000235:genetics; D004279:DNA, Viral / Q000235:genetics; D004283:Dog Diseases / Q000517:prevention & control; D004285:Dogs; D005814:Genes, Viral; D006023:Glycoproteins / Q000235:genetics / Q000276:immunology; D007564:Japan; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D011818:Rabies / Q000517:prevention & control / Q000662:veterinary; D011819:Rabies Vaccines / Q000302:isolation & purification*; D011820:Rabies virus / Q000145:classification / Q000235:genetics* / Q000276:immunology*; D017386:Sequence Homology, Amino Acid; D012689:Sequence Homology, Nucleic Acid; D013045:Species Specificity; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology; D014776:Virus Cultivation
D000911:Antibodies, Monoclonal; D000956:Antigens, Viral; D018076:DNA, Complementary; D004279:DNA, Viral; D006023:Glycoproteins; D011819:Rabies Vaccines; D014759:Viral Envelope Proteins; C064951:glycoprotein G, Rabies virus